Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process
Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process
复制标题
DOI：
10.1038/76251
复制
发表时间：
2000-06-01
期刊：
影响因子：
82.9
通讯作者：
Londei, M
中科院分区：
文献类型：
--
作者：
Mauri, C;Mars, LT;Londei, M
使用抗CD 40的激动性单克隆抗体已成为增强针对感染因子的免疫应答或对抗癌症的最有效方法之一。在这里，我们报告了先前用于引发保护性免疫应答的相同的抗CD 40单克隆抗体（FGK 45和3/23）治疗DBA/1-TCR-β转基因小鼠中慢性胶原诱导的关节炎的自身免疫炎症过程，以及DBA/1小鼠中胶原诱导的关节炎，这两种动物模型都是类风湿性关节炎。这项研究表明，针对CD 40的激动性单克隆抗体可以潜在地用于治疗慢性自身免疫性炎症过程。
The use of agonistic monoclonal antibody against CD40 has emerged as one the most effective ways to boost immune responses against infectious agents or to fight cancer. Here, we report that the same monoclonal antibodies against CD40 (FGK45 and 3/23) previously used to elicit protective immune responses treated the autoimmune inflammatory process of chronic collagen-induced arthritis in DBA/1-TCR-beta transgenic mice, as well as collagen-induced arthritis in DBA/1 mice, both animal models of rheumatoid arthritis. This study indicates that agonistic monoclonal antibody against CD40 can potentially be used to treat chronic autoimmune inflammatory processes.